癌症药物的发现依赖于临床前研究模型。从药物的发现、作用机制的厘清、给药方法的探索再到安全性管理，实验室工作不可或缺，CTLA-4和PD-1的故事就是最好的例证。但我们都清楚，临床前模型是无法完全反映人体免疫真实情况的。不空谈理论，举两个实例：常用的鼠结直肠癌模型MC38，它的高肿瘤突变负荷（TMB）能够反应...
At the endpoint, flow cytometry was performed to examine treatment-induced effects on immune profiles.Results: In the MC38 model, administration of TFF2-MSA suppressed tumor growth (TGI 38%), the combination of TFF2-MSA and anti-PD-1 had an additive effect and suppressed tumor growth ...
CT26 MC38 EL4 PD-1 PD-L1 genO-hPD‑1/hCTLA‑4 The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice. genO-hPD‑1/hGITR/hGITRL The ...
PD-L1与CLAUDIN 18.2基因人源化的CT26小鼠结肠癌细胞系 品系状态 构建中 *使用本品系发表的文献需注明: CT26-hPD-L1/hCLAUDIN 18.2 cell line (Cat. NO. NMC-230112) was purchased from Shanghai Model Organisms Center, Inc.. 相关品系 MC38-hPD-L1/hCLAUDIN 18.2 ...
Models CT26-hGDF15(NEO) Export PDF Strain Information Cell Line CT26-hGDF15(NEO) Cat. NO. NMC-230082 Model Description GDF15 gene humanized MC38 cell line Strain State Construction *Literature published using this strain should indicate: CT26-hGDF15(NEO) cell line (Cat. NO. NMC-230082) ...
联合CSF-1R抑制剂和溶瘤病毒协同增强PD-1抗体治疗效果的机制研究 在MC38和CT26皮下移植瘤模型中,抑瘤率超过92%,并且分别有82%和43%的小鼠经过治疗后肿瘤完全消退。通过机制研究发现,三者联合治疗诱发了特异的、CD8~+T细胞依赖的... 石刚,杨茜媚,张郁菁,... - 全国免疫学学术大会摘要 被引量: 0发表: 2018...
例如,结直肠MC38细胞系存在微卫星-不稳定表型( MSI )可形成T细胞炎症的肿瘤微环境,以其对ICB的强大反应。另一方面,结直肠癌CT26细胞系存在微卫星稳定( MSS )模型形成非T细胞炎症肿瘤微环境,且其对ICB反应差。MC38和CT26系的免疫表型特征和对ICB的反应性与临床观察到的MSI和MSS结直肠癌患者的相同。